Taiwan · Delayed Price · Currency is TWD Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 6.09 billion. The enterprise value is 5.69 billion.
| Market Cap | 6.09B |
| Enterprise Value | 5.69B |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 243.04 million shares outstanding. The number of shares has increased by 7.81% in one year.
| Current Share Class | 243.04M |
| Shares Outstanding | 243.04M |
| Shares Change (YoY) | +7.81% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.01% |
| Owned by Institutions (%) | n/a |
| Float | 57.17M |
Valuation Ratios
The trailing PE ratio is 25.60.
| PE Ratio | 25.60 |
| Forward PE | n/a |
| PS Ratio | 4.02 |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | 30.12 |
| P/OCF Ratio | 20.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.79, with an EV/FCF ratio of 28.16.
| EV / Earnings | 24.20 |
| EV / Sales | 3.75 |
| EV / EBITDA | 13.79 |
| EV / EBIT | 20.35 |
| EV / FCF | 28.16 |
Financial Position
The company has a current ratio of 7.39, with a Debt / Equity ratio of 0.07.
| Current Ratio | 7.39 |
| Quick Ratio | 5.05 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.46 |
| Debt / FCF | 0.94 |
| Interest Coverage | 63.43 |
Financial Efficiency
Return on equity (ROE) is 10.42% and return on invested capital (ROIC) is 10.46%.
| Return on Equity (ROE) | 10.42% |
| Return on Assets (ROA) | 6.29% |
| Return on Invested Capital (ROIC) | 10.46% |
| Return on Capital Employed (ROCE) | 9.85% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | 8.76M |
| Profits Per Employee | 1.36M |
| Employee Count | 173 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, Orient Pharma has paid 51.23 million in taxes.
| Income Tax | 51.23M |
| Effective Tax Rate | 17.88% |
Stock Price Statistics
The stock price has decreased by -3.31% in the last 52 weeks. The beta is 0.04, so Orient Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | -3.31% |
| 50-Day Moving Average | 25.22 |
| 200-Day Moving Average | 25.37 |
| Relative Strength Index (RSI) | 55.85 |
| Average Volume (20 Days) | 89,138 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.52 billion and earned 235.25 million in profits. Earnings per share was 0.98.
| Revenue | 1.52B |
| Gross Profit | 852.35M |
| Operating Income | 279.75M |
| Pretax Income | 286.47M |
| Net Income | 235.25M |
| EBITDA | 394.58M |
| EBIT | 279.75M |
| Earnings Per Share (EPS) | 0.98 |
Balance Sheet
The company has 585.05 million in cash and 189.51 million in debt, with a net cash position of 395.54 million or 1.63 per share.
| Cash & Cash Equivalents | 585.05M |
| Total Debt | 189.51M |
| Net Cash | 395.54M |
| Net Cash Per Share | 1.63 |
| Equity (Book Value) | 2.66B |
| Book Value Per Share | 10.94 |
| Working Capital | 1.10B |
Cash Flow
In the last 12 months, operating cash flow was 291.78 million and capital expenditures -89.67 million, giving a free cash flow of 202.11 million.
| Operating Cash Flow | 291.78M |
| Capital Expenditures | -89.67M |
| Depreciation & Amortization | 114.84M |
| Net Borrowing | -283.48M |
| Free Cash Flow | 202.11M |
| FCF Per Share | 0.83 |
Margins
Gross margin is 56.22%, with operating and profit margins of 18.45% and 15.52%.
| Gross Margin | 56.22% |
| Operating Margin | 18.45% |
| Pretax Margin | 18.89% |
| Profit Margin | 15.52% |
| EBITDA Margin | 26.02% |
| EBIT Margin | 18.45% |
| FCF Margin | 13.33% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.81% |
| Shareholder Yield | -7.81% |
| Earnings Yield | 3.86% |
| FCF Yield | 3.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
| Last Split Date | May 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.6500936135 |
Scores
Orient Pharma has an Altman Z-Score of 11.6 and a Piotroski F-Score of 7.
| Altman Z-Score | 11.6 |
| Piotroski F-Score | 7 |